PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease..

PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM.

PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM.

PF-05381941 (PF 05381941, PF05381941) is a potent, dual TAK1/p38a inhibitor with IC50 of 156/186 nM respectively, with good kinome selectivity against 50 representative kinases.

PF-05661014 is a potent, selective Nav1.3 inhibitor with IC50 of 0.26 uM, shows no activity for Nav1.7 (IC50>10 uM).

PF-06256142 (PF06256142) is a potent and selective orthosteric agonist of the D1 receptor with EC50 (cAMP) of 33 nM, shows exquisitely selectivity over D2.

PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively.

PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.

PF-06305591 (PF06305591) is a potent, highly selective selective NaV1.8 blocker with IC50 of 15 nM, displays no significant activity against other sodium channel subtypes, K+ channels and Ca2+ channels.

PF-06372865 is a novel potent, α2/3 functionally selective GABAA receptor positive allosteric modulator.

PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC50 of 7 nM.

PF-06426779 (PF06426779) is a potent, selective IRAK4 inhibitor with IC50 of 1 nM against full-length IRAK4 kinase and cell-based IC50 of 12 nM.

PF-06446846 (PF-6446846) is a potent, highly selective inhibitor of PCSK9 translation with IC50 of 0.3 uM for inhibition the secretion of PCSK9 by Huh7 cells.

PF-06446846 (PF-6446846) is a potent, highly selective inhibitor of PCSK9 translation with IC50 of 0.3 uM for inhibition the secretion of PCSK9 by Huh7 cells.

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.

PF-06454589 is a potent and selective LRRK2 inhibitor.

PF-06459988 (PF06459988, PF 6459988) is a potent, selective, irreversible EGFR mutants with IC50 of 13, 7, 21 and 90 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.

PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

PF-06648671 is a potent γ-secretase modulator with IC50 of 8.9 nM against Aβ42. PF-06648671 has favorable brain availability in rodent, which translated into excellent central exposure in human and robust reduction of amyloid β (Aβ) 42 in cerebrospinal fluid (CSF).

PF06650833 is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. PF06650833 is used to treat diseases such as rheumatoid arthritis, l

PF-06651600 is a potent JAK3-selective inhibitor with an IC50 of 33.1 nM.

PF-06651600 malonate is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2.

PF-06678419 (PF06678419) is a potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.44 uM.

PF-06679142 is a novel potent, orally active, α1β1γ1/α2β1γ1-isoform selective AMPK activator with Kd of 14 nM, EC50 of 22 nM for α1β1γ1-AMPK, shows minimal activity at the β2-containing isoforms (α1β2γ1, α2β2γ1, α2β2γ3).

PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus.

PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus.

PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.

PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

PF-06747711 (PF06747711) is a potent, selective, orally bioavailable RORC2 (RORγt) inverse agonist with IC50 of 4.1 nM.

PF-06751979 is a potent, selective, brain penetrant BACE1 inhibitor with binding IC50 of 7.3, 27-fold selectivity over BACE2.

PF-06764427 (PF06764427) is a potent, selective M1 muscarinic acetylcholine receptor (mAChR) positive allosteric modulator with EC50 of 55 nM, has no measurable agonist or PAM activity at the M2-M5 receptors at 10 uM.

PF-06795071 is a potent, selective, covalent Monoacylglycerol Lipase (MAGL) inhibitor with IC50 of 3 nM, >1,000-fold selectivity over FAAH.

PF-06807656 is a potent, selective renal outer medullary potassium channel (ROMK, Kir1.1a) inhibitor with IC50 of 61 nM for hROMK in patch-clamp assays.

PF-06815189 is a potent, selective phosphodiesterase 2 (PDE2) inhibitor with IC50 of 0.4 nM, >1,000-fold selectivity over PDE5.

PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay.

PF-06827443 (PF06827443) is a potent, orally bioavailable, and CNS-penetrant M1-selective positive allosteric modulator (PAM) with EC50 of 47 nM, shows no activity against M2-M5 at 10 uM.

PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities.

PF-06855800 (PF06855800) is a potent, selective, SAM competitive, BBB-penetrant, orally active inhibitor of protein arginine methyltransferase PRMT5 with Ki of 0.02 nM.

PF-06869206 is an Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1).

PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.

PF-06928215 (PF06928215) is a high affinity Cyclic GMP-AMP synthase (cGAS) inhibitor with Kd of 200 nM, IC50 of 4.9 uM.

PF-152 is a potent, highly selective and orally bioavailable MMP13 inhibitor with Ki of 1.5 nM, with no activity against MMP3 (Ki>10 uM).

PF-184298 is a potent, selective dual serotonin and noradrenaline monoamine reuptake inhibitor (SNRI) with IC50 of 6 nM and 21 nM, respectively.

PF-219061 (PF 219061, PF219061) is a potent, selective agonist of dopamine D3 receptor with EC50 of 8 nM.

PF-232798 (PF-00232798) is a potent CCR5 antagonist with IC50 of <0.1 nM in gp160 fusion assay, exhibits potent broad-spectrum anti-HIV-1 activity.

PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.

PF-2545920 a highly selective and potent PDE10A inhibitor with an IC50 of 0.37 nM.

PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.

PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM.

PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro.

PF-3635659 (PF-03635659) is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist with Ki of 0.2 nM, shows potential for the treatment of chronic obstructive pulmonary disease (COPD)..

PF-3644022 is a potent and selective, freely reversible, ATP-competitive inhibitor of MAPKAP2 (MK2) with Ki of 3 nM.

PF3845yne is a Alkyne analogues of PF3845.

PF-3893787 (ZPL 3893787) is a potent and selective H4 receptor antagonist with binding Ki of 2.4 nM.

PF-429242 is a potent inhibitor of S1P(cellular proprotein convertase sterol regulatory element-binding protein (SREBP) site 1 protease)

PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor , PF-431396 has a Kd value of 445 nM for BRD4.

PF-4363467 (PF 04363467) is a novel highly potent, brain penetrant dopamine D3/D2 receptor antagonist with Ki of 1.3/692 nM respectively, with high selectivity for D3R versus other biogenic amine receptors.

PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.

PF-46396 is a specific small-molecule inhibitor of HIV-1 Gag maturation that interferes specifically with the cleavage of the CA/SP1 (p25) Gag precursor to the mature CA (p24) protein.

PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), with a Ki of 20 nM and IC50 of 160 nM.

PF-4776548 (PF-04776548) novel HIV integrase inhibitor for treatment of HIV infections..

PF-4778574 (PF4778574) is a brain penetrant, positive allosteric modulator (potentiator) of AMPA receptor with Ki of 85 nM, increases S-AMPA-evoked responses in rat primary cortical neurons with EC50 of 45-919 nM.

PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.

PF-5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε)

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood–brain barrier.

PF-543 is a novel Sphingosine kinase 1 (SphK1, SK1) inhibitor with Ki of 3.6 nM.

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively.

PF-6274484 is an inhibitor of the EGF receptor (EGFR; IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively).

PF-6689840 (PF6689840) is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 54 nM in biochemical assays.

PF-6808472 (XO44) is a sulfonyl fluoride chemical probe that covalently labels a broad swath of the intracellular kinome with high efficiency.

PF-719 (PF719) is a potent, selective Pyk2 inhibitor with IC50 of 17 nM, displays 25-fold selectvity over FAK (IC50=469 nM); does not have significant inhibitory effects on recombinant MLCK2, p38, Akt1, or ROCK1, and very little inhibtion at Src family kinases (IC50>5 uM); selectively inhibits tyrosine phosphorylation of Pyk2 at 1 uM, but blocks both Pyk2 and FAK phosphorylation at 2.5 uM in A20 cells; reduces chemoattractant-induced migration of B-2 and MZ B cells.

PF-794 (PF794) is a potent, specific and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with IC50 of 39 nM in cell-free assays.

PF-8380 is a potent and specofic autotaxin inhibitor with an IC50 value of 2.8 nM.

PF-9184 is a potent, selective mPGES-1 (microsomal prostaglandin E synthase-1) inhibitor with IC50 of 16.5 nM.

PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.

PF-CBP1 is potent and highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) that down regulates targets of CBP in macrophages primary neurons.

PFE-360 is a novel potent, selective, brain-penetrating LRRK2 inhibitor with IC50 of 3 nM.

PFI-1 is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM.

PFI-2 is a novel potent and selective SETD7 histone lysine methyltransferase inhibitor with IC50 ~2 nM. It has > 100-fold selectivity over other methyltransferases and other non-epigenetic targets.

PFI-3 is a novel potent, selective and cell permeable inhibitor of SMARCA4 and PB1(5) bromodomains with IC50 ~ 89 nM and 48 nM respectively.

PFI-4 is a potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM).

PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) and inhibits PFKFB3 activity in cancer cells with IC50 of 20 nM.

PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.

PfKRS1 inhibitor 5 is a potent, selective, oral inhibitor of P. falciparum lysyl-tRNA synthetase (PfKRS1) with IC50 of 15 nM, displays >100-fold selectivity over Human KRS (HsKRS, IC50=1.8 uM).

PFM01 (SML1735) is a small molecule that specifically inhibits endonuclease, but not exonuclease activity of MRE11, inhibits dsDNA end resection in A549 cells with IC50 of 50-75 uM, blocks the ssDNA-binding path toward the catalytic metal ions and disrupt

PFM39 (SML1839) is a small molecule that specifically inhibits exonuclease activity of MRE11, binds in the active site similar to mirin, inhibits dsDNA end resection in A549 cells with IC50 of 50-75 uM, inhibits HR without significantly increasing NHEJ..

PGC-1α activator C80 is a potent PGC-1α acetylation activator with AC50 of 3.1 uM, induces Pck1 and G6pc expression with AC50 of 11.9 uM and 12.8 uM, reduces glucose production in hepatocytes..

PGN-9856 (PGN9856) is a novel potent, selective prostaglandin EP2 receptor agonist with pKi of > 8.3, shows higi selectivity over EP1 , EP3 , EP4 , DP, FP, IP and TP receptors; displays a potency (pEC50 >8.5) and a maximal response (increase in cAMP) comp

P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

PG-S3-001 is a small molecule STAT3 inhibitor that binds to STAT3 protein potently with Kd of 324 nM by surface plasmon resonance.

PH-002 is a small-molecule structure corrector,inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction,a potent candidate drug for the treament of AD(Alzheimer disease)

PH-797804 is a potent and selective p38 inhibitor with IC50 of 26 nM.

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs.

PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.

PHA-767491 (CAY10572) Hcl is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM.

PHA-767491 (CAY10572) is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM.

PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM, respectively.

PHA-848125(Milciclib) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM; >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.

PHCCC is a Group I metabotropic glutamate receptor antagonist (IC50 ~ 3 μM).

Phenacetin is a non-opioid analgesic without anti-inflammatory properties.

Phenazopyridine Hcl is a chemical, which has a local analgesic effect, often used to alleviate the pain, irritation, discomfort, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract.

Phen-DC 3|Phen-DC-3,Phen-DC3|DC Chemicals

Phenformin, an anti-diabetic drug, has demonstrated antitumor activity both in vitro and in vivo.

Phenindione(Rectadione)

Pheniramine Maleate ia an antihistamine and vasoconstrictor.

Phenprocoumon is closely related to warfarin and is an anticoagulant drug used to thin the blood, or stop it from clotting.

Phentolamine Mesylate is a nonselective alpha-adrenergic antagonist.

Phenylbiguanide is a 5-HT3 receptor selective agonist with an EC50 of 3.0±0.1 μM.

Phenylbutazone is used as a non-steroidal anti-inflammatory agent for the treatment of chronic pain, including the symptoms of arthritis.

Phenylpiracetam(Phenotropyl; Phenotropil) is a phenylated derivative of the nootropic drug piracetam.

Phenytoin sodium is an inactive voltage-gated sodium channel stabilizer.

PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM, and a relative binding affinity (Kd) of 150 μM in Ln229 cells.

Philanthotoxin 74 dihydrochloride (PhTx 74) is an AMPAR antagonist; inhibits GluR3 and GluR1 with IC50s of 263 and 296 nM, respectively.

Phorbol 12-myristate 13-acetate (PMA) is a PKC-activating phorbol ester, increases the intracellular Ca2+ concentration ([Ca2+]i) in a dose-dependent manner, with an EC50 of 11.7 nM.

Phosalone is a member of the organophosphate family of insecticides. It is used as both an insecticide and acaricide.

Phosphate and amino acid prodrug of Atazanavir gives four-fold improved AUC and eight-fold higher Ctrough values of Atazanavir.

Phosphonoacetohydroxamate (PhAH) is a potent Enolase inhibitor with IC50 of 53.2 nM and 62.3 nM for recombinant hENO1 and hENO2 respectively.

Phox-I1 is a small molecule inhibitor that targets the interactive site of p67(phox) with Rac GTPase with Kd of 100 nM.

PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.

PHTPP is a pyrazolo[1,5-α]pyrimidine-based ligand that acts as a full antagonist of estrogen ERβ receptors with 36-fold selectivity over ERα.

PHY34 is a potent autophagy inhibitor with cytotoxic effects by inhibiting autophagy at a late stage (MDA-MB-435 IC50=23 nM, MDA-MB-231 IC50=5.2 nM).

Phytochemical alkaloid found in medicinal plants. Anti-inflammatory. Exhibits neuroprotective, antioxidative and gastrointestinal modulatory activities.

PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (IC50= 2 nM), p110beta (IC50= 3 nM), p110delta (IC50= 3 nM), and p110gamma (IC50= 15 nM), less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

PI-16552 is a potent, specific poly(ADP-ribose) glycohydrolase (PARG) inhibitor with IC50 of 1.7 uM.

PI-1840 is a potent and selective inhibitor for chymotrypsin-like (CT-L) (IC50 value = 27 ± 0.14 nM) over trypsin-like and peptidylglutamyl peptide hydrolyzing (IC50 values >100 μM) activities of the proteasome.

PI-273 (PI273) is a potent, specific, substrate-competitive small molecule inhibitor of PI4KIIα with IC50 of 0.47 uM.

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively. Antitumor activity.

PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity.

PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor with cell IC50 of 12 nM (in PTEN null MDA-MB-468 cell) and 47 nM (in Jeko-1 B-cell), respectively.

PI3K-IN-2 is a PI3K inhibitor, inhibits pPKB and pS6 with "++++/+++(+)" in A2058 melanoma cell.

PI3K-IN-8q is a potent, selective dual p110α/p110δ inhibitor with Ki app of 3.3/8.36 nM respectively.

PI3Kα-IN-1 is a potent, selective, ATP-competitive dual PI3Kα/mTOR inhibitor with IC50 of 0.5/104 nM respectively.

PI3Kα-IN-5 is a potent, selective PI3Kα inhibitor with enzyme IC50 and cell IC50 of 6 nM and 87 nM respectively, exhibits 100-fold selectivity over PI3Kβ.

PI3Kγ is required for for T-cell and B-cell as well as mast cell migration and degranulation. As such, these kinases are attractive targets for potential anti-infmamatory drugs. TASP0415914 has shown excellent results in cell based assays. It is orally av

PI3kδ inhibitor 1 is a potent and selective inhibitor of isoform of PI3Kδ; useful for treating disorders mediated by lipid kinases such as inflammation, immunol disorders, and cancer.

PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.

PI3Kδ-IN-7n is a highly potent and selective PI3Kδ inhibitor with IC50 of 0.9 nM, displays high selectivity (>1,500-fold) over PI3Kα, PI3Kβ, PI3Kγ (IC50>1.5 uM).

PI4KIIIβ-IN-9 is a potent and selective inhibitor of PI4KIIIβ (IC50=7 nM).

PIAA is a TBK1/IKKε inhibitor with IC50 of 0.40/1.07 uM, selectively accelerates proliferation of β-cells.

Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Piclamilast (RP-73401) is a potent and highly selective PDE4 inhibitor with IC50 of 1.2 nM.

Pico145 is a highly potent, subtype-selective TRPC1/4/5 channels inhibitor with potency ranged from 9 to 1300 pM, depending on the TRPC1/4/5 subtype and activation mechanism.

Picoxystrobin is an methoxyacrylate strobilurin fungicide designed for the control of wide range of cereal diseases.

Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM.

Pidotimod is a synthetic dipeptide with immunological modulatory activity on both the adaptive and innate immune responses. This compound has been shown to induce dendritic cell maturation and up-regulate the expression of HLA-DR and co-stimulatory molecu

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.

Pifithrin-β HBr (Cyclic Pifithrin-α HBr) is a potent p53 inhibitor with IC50 of 23 uM in an antiproliferative assay in the human ovarian carcinoma cell line, IGROV-1.

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.

PIK-293 is a PI3K inhibitor, mostly for PI3Kδ with IC50 of 0.24 μM, 500-, 100- and 50-fold less potent to PI3Kα/β/γ, respectively.

PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3Kα/β/γ, respectively.

PIK-75 is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM.

PIK-90 is a potent and cell permeable inhibitor of p110α, p110β, p110γ and p110δ with IC50 of 11 nM, 350 nM, 18 nM and 58 nM, respectively.

PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.

PIK-III, which is a selective inhibitor of ​VPS34 enzymatic activity, inhibits autophagy and de novo lipidation of LC3 and leads to the stabilization of autophagy substrates.

Pilaralisib (SAR245408; XL147) is selective oral pan-PI3K inhibitor.

Pilsicainide hydrochloride is a selective Na+ channel blocker (IC30 values are 9 and 60 μM for inward Na+ and Ca2+ currents respectively). Shows antiarrhythmic effects in vivo. Orally active.

Pim inhibitor 28 is a potent, selective inhibitor of Pim1/2 with IC50 of 0.05 nM for both, demonstrates on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors..

PIM/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively; also inhibits MPSK1 and TNIK.

PIM447 is novel pan-PIM kinase inhibitor, including Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase.

Pimavanserin(ACP-103) is a potent and selective 5-HT2A receptor inverse agonist with mean pIC50 of with 8.7 in the cell-based functional assay.

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.

Pim-IN-22m is a potent, selective Pim1/Pim2 inhibitor with IC50 of 24/95 pM respectively.

Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.

Pimodivir(VX-787) is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. 

Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor, also is an inhbitor of STAT5.

Pin1 inhibitor API-1 (API-1) is a potent, specific inhibitor of peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) and inhibits Pin1 cis-trans isomerizing activity with IC50 of 72.3 nM, displays remarkable selectivity over other peptidyl-prolyl

PIN1 inhibitor VS10 is a novel potent small molecule inhibitor of PIN1 (peptidyl-prolyl cis-trans isomerase, NIMA-interacting 1), inhibits human PIN1 isomerization with IC50 of 13.4 uM, displays >2-fold more potency than ATRA.

Pinacidil monohydrate, an antihypertensive drug, is a potassium channel activator.

Pioglitazone (Actos)

Pioglitazone Hydrochloride is the hydrochloride salt preparation of Pioglitazone, a specific ligand of PPAR-γ (peroxisome proliferator-activated receptor-γ). Pioglitazone is a thiazolidinedione compound described to produce antiinflammatory and antiarteri

Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.

Piperaquine Phosphate

Piperazine Erastin is an analog of Erastin, which can induces ferroptosis in cancer cells, an iron-dependent form of nonapoptotic cell death..

Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53.

Piperoxan hydrochloride is an α2 adrenoceptor antagonist.

Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.

Piracetam is a cyclic derivative of the neurotransmitter ã-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.

Piragliatin (RO 4389620.

Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin, which is an inhibitor of Topo II.

Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Pirlimycin

Pirlindole is a novel potent inhibitor of Enteroviruse that targets Viral Protein 2C, inhibits EV-B and EV-D through the inhibition of genome replication (CV-B3 EC50=9.91 uM). .

Pirmenol hydrochloride inhibits IK.ACh by blocking muscarinic receptors. The IC50 of Pirmenol for inhibition of Carbachol-induced IK.ACh is 0.1 μM.

Pirmenol inhibits IK.ACh by blocking muscarinic receptors. The IC50 of Pirmenol for inhibition of Carbachol-induced IK.ACh is 0.1 μM.

Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds; potent human rhinovirus (HRV) capsid-binding inhibitor.

Piroxicam (Feldene) is a non-selective COX inhibitor with an IC50 of 6 mM.

PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain binding with IC50 of 30 uM, Kd of 43.2 uM.

Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis.

Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH o

Pitolisant Hcl(BF2.649;Ciproxidine ) is a novel, potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pivmecillinam(Amdinocillin pivoxil) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pizotifen malate

Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor..

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

PJ-68 is a potent, selective inhibitor of arginine methyltransferase PRMT5 with IC50 of 517 nM, shows no inhibitory activity against type I PRMT family members ( (PRMT1, 3, 4, 6, and 8).

PK4C9 (Homocarbonyltopsentin) is a small-molecule stem-loop RNA structure TSL2-binding compound (EC50=16.1 uM) that increases SMN2 exon 7 (E7) splicing and rescues downstream molecular alterations in SMA cells.